$6.1M
+$6.1M this year2 filings since 2026 · latest Equity filed
Tempest Therapeutics is a clinical-stage biotechnology company in Brisbane, California, developing in vivo CAR-T cell therapies for autoimmune disease and cancer. Following an all-stock acquisition of dual-targeting CAR-T assets from Factor Bioscience that closed in early 2026, the company unveiled a next-generation in vivo CAR-T pipeline in July 2026. Its approach pairs a CD7-targeted mRNA lipid nanoparticle delivery platform with a dual-targeting CAR architecture, engineering CAR-T cells inside the patient rather than through ex vivo manufacturing. Tempest also retains earlier small-molecule oncology programs, TPST-1120 and TPST-1495.
What sets it apart
Combines a CD7-targeted lipid nanoparticle delivery system with a dual-target CD19/BCMA CAR architecture to generate CAR-T cells in vivo, removing the cell-manufacturing step that makes conventional CAR-T slow and costly, and targeting both CD4+ and CD8+ T-cell populations.
The lead in vivo CAR-T candidate, pairing Tempest's CD7-targeted mRNA lipid nanoparticle (CD7-tLNP) delivery platform with a dual-targeting CD19/BCMA chimeric antigen receptor.
